 | • レポートコード：20QY06-04726 • 出版社/出版日：QYResearch / 2020年6月1日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、140ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、化学療法誘発末梢神経障害治療のグローバル市場について種類別（カルシウムチャンネルα2-deltaリガンド、抗うつ薬、オピオイド、その他）、用途別（白金剤、タキサン、ビンカアルカロイド、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・化学療法誘発末梢神経障害治療市場の概要 ・世界の主要地域別化学療法誘発末梢神経障害治療市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の化学療法誘発末梢神経障害治療市場規模2015-2026：種類別（カルシウムチャンネルα2-deltaリガンド、抗うつ薬、オピオイド、その他） ・世界の化学療法誘発末梢神経障害治療市場規模2015-2026：用途別（白金剤、タキサン、ビンカアルカロイド、その他） ・化学療法誘発末梢神経障害治療の北米市場規模2015-2020 ・化学療法誘発末梢神経障害治療のヨーロッパ市場規模2015-2020 ・化学療法誘発末梢神経障害治療の中国市場規模2015-2020 ・化学療法誘発末梢神経障害治療の日本市場規模2015-2020 ・化学療法誘発末梢神経障害治療の東南アジア市場規模2015-2020 ・化学療法誘発末梢神経障害治療のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Aptinyx Inc、Asahi Kasei Pharma Corp、Regenacy Pharmaceuticals、MAKScientific LLC、Metys Pharmaceuticals AG、Nemus Bioscience Inc、PledPharma、Sova Pharmaceuticals Inc、DermaXon LLC、Kineta Inc、Krenitsky Pharmaceuticals Inc、PeriphaGen、Apexian Pharma、WinSanTor、Solasia Pharma K.K.） ・化学療法誘発末梢神経障害治療の製造コスト分析 ・販売チャネル、流通業者、顧客 ・化学療法誘発末梢神経障害治療の市場動向・機会・課題 ・調査の結論 |
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
By region, the United States has the highest share of income, reaching 47.25 percent in 2019.
Market Analysis and Insights: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Chemotherapy Induced Peripheral Neuropathy Treatment market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Chemotherapy Induced Peripheral Neuropathy Treatment industry.
Based on our recent survey, we have several different scenarios about the Chemotherapy Induced Peripheral Neuropathy Treatment YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 1477.4 million in 2019. The market size of Chemotherapy Induced Peripheral Neuropathy Treatment will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
Global Chemotherapy Induced Peripheral Neuropathy Treatment Scope and Market Size
The global Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy Induced Peripheral Neuropathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented into
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Segment by Application, the Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented into
Platinum Agents
Taxanes
Vinca Alkaloids
Others
The Chemotherapy Induced Peripheral Neuropathy Treatment market is analysed and market size information is provided by regions (countries). Segment by Application, the Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Analysis
Chemotherapy Induced Peripheral Neuropathy Treatment market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Chemotherapy Induced Peripheral Neuropathy Treatment business, the date to enter into the Chemotherapy Induced Peripheral Neuropathy Treatment market, Chemotherapy Induced Peripheral Neuropathy Treatment product introduction, recent developments, etc.
The major vendors covered:
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
Solasia Pharma K.K.
1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Product Scope
1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type
1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2026)
1.2.2 Calcium Channel α2-delta Ligands
1.2.3 Antidepressants
1.2.4 Opioids
1.2.5 Others
1.3 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Comparison by Application (2020-2026)
1.3.2 Platinum Agents
1.3.3 Taxanes
1.3.4 Vinca Alkaloids
1.3.5 Others
1.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts (2015-2026)
1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Growth Rate (2015-2026)
1.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Growth Rate (2015-2026)
1.4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Chemotherapy Induced Peripheral Neuropathy Treatment Industry Impact
1.5.1 How the Covid-19 is Affecting the Chemotherapy Induced Peripheral Neuropathy Treatment Industry
1.5.1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Chemotherapy Induced Peripheral Neuropathy Treatment Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Chemotherapy Induced Peripheral Neuropathy Treatment Players to Combat Covid-19 Impact
2 Chemotherapy Induced Peripheral Neuropathy Treatment Estimate and Forecast by Region
2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2015-2020)
2.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2015-2020)
2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2015-2026)
2.4.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2015-2026)
2.4.3 China Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2015-2026)
2.4.4 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2015-2026)
2.4.6 India Chemotherapy Induced Peripheral Neuropathy Treatment Estimates and Projections (2015-2026)
3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Competition Landscape by Players
3.1 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Sales (2015-2020)
3.2 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Revenue (2015-2020)
3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2019)
3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price by Company (2015-2020)
3.5 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Chemotherapy Induced Peripheral Neuropathy Treatment Players (Opinion Leaders)
4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Review by Type (2015-2020)
4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2015-2020)
4.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2014-2020)
4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Type (2021-2026)
4.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Type (2021-2026)
4.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Type (2021-2026)
5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Review by Application (2015-2020)
5.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020)
5.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2015-2020)
5.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2015-2020)
5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Application (2021-2026)
5.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Application (2021-2026)
5.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Application (2021-2026)
3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
3.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2015-2020)
3.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
3.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020)
4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
4.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2015-2020)
4.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
4.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020)
5 China Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
5.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2015-2020)
5.3 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
5.4 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020)
6 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
6.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2015-2020)
6.3 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
6.4 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020)
7 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
7.2 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020)
8 India Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures
8.2 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2015-2020)
8.3 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
8.4 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Chemotherapy Induced Peripheral Neuropathy Treatment Business
12.1 Aptinyx Inc
12.1.1 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.1.2 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.1.5 Aptinyx Inc Recent Development
12.2 Asahi Kasei Pharma Corp
12.2.1 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.2.2 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.2.5 Asahi Kasei Pharma Corp Recent Development
12.3 Regenacy Pharmaceuticals
12.3.1 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.3.2 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.3.5 Regenacy Pharmaceuticals Recent Development
12.4 MAKScientific LLC
12.4.1 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.4.2 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.4.5 MAKScientific LLC Recent Development
12.5 Metys Pharmaceuticals AG
12.5.1 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.5.2 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.5.5 Metys Pharmaceuticals AG Recent Development
12.6 Nemus Bioscience Inc
12.6.1 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.6.2 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.6.5 Nemus Bioscience Inc Recent Development
12.7 PledPharma
12.7.1 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.7.2 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.7.5 PledPharma Recent Development
12.8 Sova Pharmaceuticals Inc
12.8.1 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.8.2 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.8.5 Sova Pharmaceuticals Inc Recent Development
12.9 DermaXon LLC
12.9.1 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.9.2 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.9.5 DermaXon LLC Recent Development
12.10 Kineta Inc
12.10.1 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.10.2 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.10.5 Kineta Inc Recent Development
12.11 Krenitsky Pharmaceuticals Inc
12.11.1 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.11.2 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.11.5 Krenitsky Pharmaceuticals Inc Recent Development
12.12 PeriphaGen
12.12.1 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.12.2 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.12.5 PeriphaGen Recent Development
12.13 Apexian Pharma
12.13.1 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.13.2 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.13.5 Apexian Pharma Recent Development
12.14 WinSanTor
12.14.1 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.14.2 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.14.5 WinSanTor Recent Development
12.15 Solasia Pharma K.K.
12.15.1 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Corporation Information
12.15.2 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Business Overview and Total Revenue
12.15.3 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
12.15.5 Solasia Pharma K.K. Recent Development
13 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Cost Analysis
13.1 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
13.4 Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
14.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate by Type (2020-2026)
Table 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Chemotherapy Induced Peripheral Neuropathy Treatment Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Chemotherapy Induced Peripheral Neuropathy Treatment Players to Combat Covid-19 Impact
Table 8. Global Market Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Region (2015-2020)
Table 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2015-2020)
Table 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Region (2015-2020)
Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Forecast by Region (2021-2026)
Table 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share Forecast by Region (2021-2026)
Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment (K Units) of Key Companies (2015-2020)
Table 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Company (2015-2020)
Table 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Company (2015-2020)
Table 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2019)
Table 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Average Price (US$/Unit) of Key Company (2015-2020)
Table 23. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Sites and Area Served
Table 24. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Chemotherapy Induced Peripheral Neuropathy Treatment Players
Table 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2015-2020)
Table 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2015-2020)
Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (K Units) by Type (2015-2020)
Table 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2021-2026)
Table 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2021-2026)
Table 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (K Units) by Type (2021-2026)
Table 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2015-2020)
Table 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Application (2015-2020)
Table 37. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (K Units) by Application (2015-2020)
Table 39. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2021-2026)
Table 40. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Application (2021-2026)
Table 41. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2021-2026)
Table 43. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price (K Units) by Application (2021-2026)
Table 44. United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Company (2015-2020)
Table 45. United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2015-2020)
Table 46. United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2015-2020)
Table 47. United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
Table 48. United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2015-2020)
Table 49. United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020)
Table 50. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Company (2015-2020)
Table 51. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2015-2020)
Table 52. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2015-2020)
Table 53. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
Table 54. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2015-2020)
Table 55. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
Table 56. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Company (2015-2020)
Table 57. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2015-2020)
Table 58. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2015-2020)
Table 59. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
Table 60. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2015-2020)
Table 61. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020)
Table 62. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Company (2015-2020)
Table 63. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2015-2020)
Table 64. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2015-2020)
Table 65. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
Table 66. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2015-2020)
Table 67. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Company (2015-2020)
Table 69. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2015-2020)
Table 71. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2015-2020)
Table 73. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020)
Table 74. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Company (2015-2020)
Table 75. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2015-2020)
Table 76. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Type (2015-2020)
Table 77. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2015-2020)
Table 78. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) by Application (2015-2020)
Table 79. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2015-2020)
Table 80. Aptinyx Inc Corporation Information
Table 81. Aptinyx Inc Description and Business Overview
Table 82. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 83. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 84. Aptinyx Inc Recent Development
Table 85. Asahi Kasei Pharma Corp Corporation Information
Table 86. Asahi Kasei Pharma Corp Description and Business Overview
Table 87. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 88. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 89. Asahi Kasei Pharma Corp Recent Development
Table 90. Regenacy Pharmaceuticals Corporation Information
Table 91. Regenacy Pharmaceuticals Description and Business Overview
Table 92. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 93. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 94. Regenacy Pharmaceuticals Recent Development
Table 95. MAKScientific LLC Corporation Information
Table 96. MAKScientific LLC Description and Business Overview
Table 97. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 98. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 99. MAKScientific LLC Recent Development
Table 100. Metys Pharmaceuticals AG Corporation Information
Table 101. Metys Pharmaceuticals AG Description and Business Overview
Table 102. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 103. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 104. Metys Pharmaceuticals AG Recent Development
Table 105. Nemus Bioscience Inc Corporation Information
Table 106. Nemus Bioscience Inc Description and Business Overview
Table 107. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 108. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 109. Nemus Bioscience Inc Recent Development
Table 110. PledPharma Corporation Information
Table 111. PledPharma Description and Business Overview
Table 112. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 113. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 114. PledPharma Recent Development
Table 115. Sova Pharmaceuticals Inc Corporation Information
Table 116. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 117. Sova Pharmaceuticals Inc Description and Business Overview
Table 118. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 119. Sova Pharmaceuticals Inc Recent Development
Table 120. DermaXon LLC Corporation Information
Table 121. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 122. DermaXon LLC Description and Business Overview
Table 123. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 124. DermaXon LLC Recent Development
Table 125. Kineta Inc Corporation Information
Table 126. Kineta Inc Description and Business Overview
Table 127. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 128. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 129. Kineta Inc Recent Development
Table 130. Krenitsky Pharmaceuticals Inc Corporation Information
Table 131. Krenitsky Pharmaceuticals Inc Description and Business Overview
Table 132. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 133. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 134. Krenitsky Pharmaceuticals Inc Recent Development
Table 135. PeriphaGen Corporation Information
Table 136. PeriphaGen Description and Business Overview
Table 137. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 138. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 139. PeriphaGen Recent Development
Table 140. Apexian Pharma Corporation Information
Table 141. Apexian Pharma Description and Business Overview
Table 142. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 143. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 144. Apexian Pharma Recent Development
Table 145. WinSanTor Corporation Information
Table 146. WinSanTor Description and Business Overview
Table 147. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table 148. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 149. WinSanTor Recent Development
Table . Solasia Pharma K.K. Corporation Information
Table . Solasia Pharma K.K. Description and Business Overview
Table . Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2015-2020)
Table . Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table . Solasia Pharma K.K. Recent Development
Table 155. Production Base and Market Concentration Rate of Raw Material
Table 156. Key Suppliers of Raw Materials
Table 157. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List
Table 158. Chemotherapy Induced Peripheral Neuropathy Treatment Customers List
Table 159. Market Key Trends
Table 160. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 161. Key Challenges
Table 162. Research Programs/Design for This Report
Table 163. Key Data Information from Secondary Sources
Table 164. Key Data Information from Primary Sources
List of Figures
Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture
Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application in 2020 & 2026
Figure 6. Platinum Agents Examples
Figure 7. Taxanes Examples
Figure 8. Vinca Alkaloids Examples
Figure 9. Others Examples
Figure 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate (2015-2026)
Figure 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (US$ Million) Growth Rate (2015-2026)
Figure 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Trends Growth Rate (2015-2026) (US$/Unit)
Figure 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region: 2015 VS 2020
Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region: 2021 VS 2026
Figure 15. United States Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Growth Rate (2015-2026)
Figure 16. United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units) Growth Rate (2015-2026)
Figure 17. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Million USD) Growth Rate (2015-2026)
Figure 19. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Million USD) and Growth Rate (2015-2026)
Figure 21. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Million USD) Growth Rate (2015-2026)
Figure 25. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (Million USD) Growth Rate (2015-2026)
Figure 26. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales (Million USD) Growth Rate (2015-2026)
Figure 27. Global 5 Largest Chemotherapy Induced Peripheral Neuropathy Treatment Players Market Share by Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment 2015 & 2019
Figure 28. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2015-2020)
Figure 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate by Type in 2015 & 2019
Figure 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2015-2020)
Figure 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate by Application in 2015 & 2019
Figure 33. United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2019
Figure 34. United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2019
Figure 35. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company in 2019
Figure 36. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2019
Figure 37. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2019
Figure 38. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company in 2019
Figure 39. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2019
Figure 40. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2019
Figure 41. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company in 2019
Figure 42. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2019
Figure 43. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2019
Figure 44. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company in 2019
Figure 45. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2019
Figure 46. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2019
Figure 47. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company in 2019
Figure 48. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2019
Figure 49. India Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2019
Figure 50. Aptinyx Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Asahi Kasei Pharma Corp Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Regenacy Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. MAKScientific LLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Metys Pharmaceuticals AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Nemus Bioscience Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. PledPharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Sova Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. DermaXon LLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Kineta Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Krenitsky Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. PeriphaGen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Apexian Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. WinSanTor Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Solasia Pharma K.K. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Key Raw Materials Price Trend
Figure 66. Manufacturing Cost Structure of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 67. Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure 68. Chemotherapy Induced Peripheral Neuropathy Treatment Industrial Chain Analysis
Figure 69. Channels of Distribution
Figure 70. Distributors Profiles
Figure 71. Porter's Five Forces Analysis
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
化学療法誘発性好中球減少症（CIN）治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Chemotherapy-Induced Neutropenia (CIN) Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. …- 化学療法誘発悪心＆嘔吐（CINV）用薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global ChemOtherapy Induced Nausea and Vomiting （CINV） Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2…
- 糖尿病性神経障害治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Diabetic Neuropathy Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.9% in the forecast period of 2020 to 2025 and will expected to reach USD 5450.8 million by 2025, from USD 4676.5 million in 2019. The Diabet…
- 化学療法用椅子の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Chemotherapy Chairs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.2% in the forecast period of 2020 to 2025 and will expected to reach USD 511.8 million by 2025, from USD 451.2 million in 2019. The Chemotherapy Chair…
- 骨髄性白血病細胞分化誘導タンパク質Mcl-1の世界市場レポート2020 Market Analysis and Insights: Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market The global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during…